(Q36740041)

16 August 2017

1 reference

title

COX-2 inhibition: a possible role in the management of prostate cancer? (English)

1 reference

16 August 2017

1 reference

Sooriakumaran P

1

1 reference

16 August 2017

Langley SE

series ordinal

2

1 reference

16 August 2017

Laing RW

series ordinal

3

1 reference

16 August 2017

Coley HM

series ordinal

4

1 reference

16 August 2017

publication date

1 February 2007

1 reference

16 August 2017

published in

Journal of Chemotherapy

1 reference

16 August 2017

volume

19

1 reference

16 August 2017

issue

1

1 reference

16 August 2017

page(s)

21-32

1 reference

Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

21 January 2018

Cyclooxygenases 1 and 2

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Cyclooxygenase-1 and -2 isoenzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

COX-2 inhibition and prevention of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Renal effects of COX-2-selective inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Increased risk of cardiovascular events with coxibs and NSAIDs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Risk of cardiovascular events and rofecoxib: cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Expression of cyclooxygenase-2 in prostate carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Chronic immune activation and inflammation as the cause of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Sexual behaviour, STDs and risks for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

The diet, prostate inflammation, and the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

The role of cyclooxygenase-2 in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Tumor necrosis factor-alpha stimulates gastric epithelial cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Enhanced cyclooxygenase-2 mRNA expression in human gingival fibroblasts induced by cell contact with human lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Testosterone and prostate specific antigen stimulate generation of reactive oxygen species in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

The biology of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Genotype-phenotype correlation in murine Apc mutation: differences in enterocyte migration and response to sulindac

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Novel approaches to treat asymptomatic, hormone-naive patients with rising prostate-specific antigen after primary treatment for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

The role of cyclooxygenase-2 inhibition for the prevention and treatment of prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2007.19.1.21

21 January 2018

Identifiers

DOI

10.1179/JOC.2007.19.1.21

1 reference

16 August 2017

1 reference